top of page
Search

Executive Buying Newsletter July 15, 2024

  • Jul 16, 2024
  • 1 min read

We are not holding any previous positions.


We are removing Apple Inc. (SYMBOL: AAPL), Costco Wholesale Corp (SYMBOL:COST), Eli Lilly (SYMBOL:LLY), Ultra S&P500 (SYMBOL:SSO), Microsoft Corp (SYMBOL:MSFT), Invesco QQQ Trust (SYMBOL:QQQ), Alphabet Inc A (SYMBOL:GOOGL) and NVIDIA Corp (SYMBOL: NVDA).


Below is a summary of our performance since our last update:



This update we have received an overbought signal on the broader markets. Over bought conditions can remain that way for a long time. In order to correct this condition and make the risk/reward ratio favorable again we would be looking for sideways action or a correction in prices from their current levels. This specific condition for our model rarely occurs but could last more than one update. The model is signaling 100% cash and will continue to be positioned that way until at least our next update.


Thank you for putting your trust and time into my ability to create a model that will hopefully add value to all of us. I've started this journey in 2000 as a Nasdaq Market Maker. I also worked as a Proprietary trader, Financial Advisor and currently I manage a hedge fund. I have learned many lessons throughout my career and still continue to learn to this day. I look forward to sharing my experiences with you via this newsletter.


Thank you,


Dominick Manaro










 
 
 

Recent Posts

See All
Executive Buying Newsletter August 3, 2026

Please see the updated list: AMGN (Amgen Inc.) Amgen has delivered solid results with Q1 earnings that beat expectations and raised full-year guidance, supported by steady demand for key products. Sha

 
 
 
Executive Buying Newsletter July 15, 2026

Mid-July 2026 Edition This market has been very choppy since mid-May. It looks like it will break out of this consolidation area one way or another very soon. Here are the list of companies on our new

 
 
 
Executive Buying Newsletter July 3, 2026

Please review the following additions to the newsletter: AMGN (Amgen Inc.) Amgen continues to demonstrate resilience in the biotech sector with solid financial performance. In Q1 2026, the company rep

 
 
 

Comments


bottom of page